Highlights - 6th EMA-AESGP bilateral meeting
Submitted by Anonymous (not verified) on 13 February 2026 - 14:25
Highlights - 6th EMA-AESGP bilateral meeting
Medicinal products for human use: monthly figures - January 2026
Submitted by Anonymous (not verified) on 13 February 2026 - 14:21
Medicinal products for human use: monthly figures - January 2026
Human medicines European public assessment report (EPAR): Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris, emtricitabine,rilpivirine,tenofovir alafenamide, Date of authorisation: 19/08/2025, Status: Authorised
Submitted by Anonymous (not verified) on 13 February 2026 - 14:20
Human medicines European public assessment report (EPAR): Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris, emtricitabine,rilpivirine,tenofovir alafenamide, Date of authorisation: 19/08/2025, Status: Authorised
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9 - 12 February 2026
Submitted by Anonymous (not verified) on 13 February 2026 - 11:30
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9 - 12 February 2026
Referral: Levamisole-containing medicinal products, levamisole, associated names: Decaris,Levamisol Arena Article 31 referrals Recommendation provided by Pharmacovigilance Risk Assessment Committee, 13/02/2026
Submitted by Anonymous (not verified) on 13 February 2026 - 11:30
Referral: Levamisole-containing medicinal products, levamisole, associated names: Decaris,Levamisol Arena Article 31 referrals Recommendation provided by Pharmacovigilance Risk Assessment Committee, 13/02/2026
EMA recommends withdrawal of marketing authorisations for levamisole medicines
Submitted by Anonymous (not verified) on 13 February 2026 - 11:29
EMA recommends withdrawal of marketing authorisations for levamisole medicines
Medicine shortage communications (MSC)
Submitted by Anonymous (not verified) on 13 February 2026 - 10:43
Medicine shortage communications (MSC)
Medicine shortage communication (MSC): Natpar (parathyroid hormone) (25, 50, 75 and 100 micrograms/dose powder and solvent for solution for injection)
Submitted by Anonymous (not verified) on 13 February 2026 - 10:41
Medicine shortage communication (MSC): Natpar (parathyroid hormone) (25, 50, 75 and 100 micrograms/dose powder and solvent for solution for injection)
Clinical investigation of medicinal products in the treatment of Myasthenia Gravis
Submitted by Anonymous (not verified) on 13 February 2026 - 9:11
Clinical investigation of medicinal products in the treatment of Myasthenia Gravis
Concept paper on the need of a guideline on clinical investigation of medicinal products in the treatment of Myasthenia Gravis
Submitted by Anonymous (not verified) on 13 February 2026 - 9:07
Concept paper on the need of a guideline on clinical investigation of medicinal products in the treatment of Myasthenia Gravis